Decreased analgesic effect of morphine, but not buprenorphine, in patients with advanced P-glycoprotein+ cancers

Pharmacological Reports

Volumn 64, Issue 4, 2012, Pages 870-877

  Wang, Jun ^a   Cai, Bing ^a   Huang, Dong Xiao ^a   Yang, Shu Dong ^a   Guo, Lin ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Analgesia; Buprenorphine; Morphine; P glycoprotein; Pain

Indexed keywords

ANTINEOPLASTIC AGENT; BUPRENORPHINE; DICLOFENAC; MORPHINE; MULTIDRUG RESISTANCE PROTEIN; TRAMADOL;

ADULT; ADVANCED CANCER; AGED; ANALGESIA; ANALGESIC ACTIVITY; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PAIN; PATIENT CONTROLLED ANALGESIA; PROTEIN EXPRESSION; VISUAL ANALOG SCALE;

EID: 84867670021     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70881-2     Document Type: Article

References (32)

1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol, 1999, 39, 361-398. (Pubitemid 29222564)
2. Aquilante CL, Letrent SP, Pollack GM, Brouwer KL: Increased brain P-glycoprotein in morphine tolerant rats. Life Sci, 2000, 66, 47-51.
3. Beghin D, Delongeas JL, Claude N, Farinotti R, Forestier F, Gil S: Comparative effects of drugs on Pglycoprotein expression and activity using rat and human trophoblast models.Toxicol In Vitro, 2010, 24, 630-637.
4. Boström E, Hammarlund-Udenaes M, Simonsson US: Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine. Anesthesiology, 2008, 108, 495-505. (Pubitemid 351304243)
5. Ederoth P, Tunblad K, Bouw R, Lundberg CJ, Ungerstedt U, Nordström CH, Hammarlund-Udenaes M: Blood-brain barrier transport of morphine in patients with severe brain trauma. Br J Clin Pharmacol, 2004, 57, 427-435. (Pubitemid 38519647)
6. El-Sayed GG: A new catheter technique for thoracic subarachnoid neurolysis in advanced lung cancer patients. Pain Pract, 2007, 7, 27-30.
7. Hamabe W, Maeda T, Fukazawa Y, Kumamoto K, Shang LQ, Yamamoto A, Yamamoto C: P-glycoprotein ATPase activating effect of opioid analgesics and their P-glycoprotein-dependent antinociception in mice. Pharmacol Biochem Behav, 2006, 85, 629-636. (Pubitemid 46097074)
8. Hassan HE, Mercer SL, Cunningham CW, Coop A, Eddington ND: Evaluation of the P-glycoprotein (Abcb1) affinity status of a series of morphine analogs: comparative study with meperidine analogs to identify opioids with minimal P-glycoprotein interactions. Int J Pharm, 2009, 22, 48-54.
9. Hassan HE, Myers AL, Coop A, Eddington ND: Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation. J Pharm Sci, 2009, 98, 4928-4940.
10. Heel RC, Brogden RN, Speight TM, Avery GS: Buprenorphine: A review of its pharmacological properties and therapeutic efficacy. Drugs, 1979, 17, 81-110. (Pubitemid 11144150)
11. Hemauer SJ, Patrikeeva SL, Nanovskaya TN, Hankins GD, Ahmed MS: Opiates inhibit paclitaxel uptake by P-glycoproteinin preparations of human placental inside-out vesicles. Biochem Pharmacol, 2009, 78, 1272-1278.
12. Ishikawa T, Hirano H, Onishi Y, Sakurai A, Tarui S: Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: highspeed screening and structure-activity relationship analyses. Drug Metab Pharmacokinet, 2004, 9, 1-14.
13. Kamei J, Hirano S, Miyata S, Saitoh A, Onodera K: Effects of first- and second-generation histamine- H1-receptor antagonists on the pentobarbital- induced loss of the righting reflex in streptozotocin-induced diabetic mice. J Pharmacol Sci, 2005, 97, 266-272. (Pubitemid 40410267)
14. Kay B: A double-blind comparison of morphine and buprenorphine in the prevention of pain after operation. Br J Anaesth, 1978, 50, 605-609.
15. Kerb R: Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett, 2006, 234, 4-33.
16. Leppert W: Role of oxycodone and oxycodone/naloxone in cancer pain management. Pharmacol Rep, 2010, 62, 578-591.
17. Leppert W, Mikołajczak P, Kamińska E, Szulc M: Analgesia and serum assays of controlled-release dihydrocodeine and metabolites in cancer patients with pain. Pharmacol Rep, 2012, 64, 84-93.
18. Letrent SP, Polli JW, Humphreys JE, Pollack GM, Brouwer KR, Brouwer KL: P-glycoprotein-mediated transport of morphine in brain capillary endothelial cells.Biochem Pharmacol, 1999, 58, 951-957. (Pubitemid 29361461)
19. Mogil JS: The genetic mediation of individual differences in sensitivity to pain and its inhibition. Proc Natl Acad Sci USA, 1999, 96, 7744-7751.
20. Ohtani M, Kotaki H, Nishitateno K, Sawada Y, Iga T: Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther, 1997, 281, 428-433. (Pubitemid 27203097)
21. Ohtani M, Kotaki H, Sawada Y, Iga T: Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther, 1995, 272, 505-510.
22. Ohtsuki S, Hori S, Terasaki T: Molecular mechanisms of drug influx and efflux transport at the blood-brain barrier. Folia Pharmacol Jpn, 2003, 122, 55-64. (Pubitemid 36834417)
23. Ose A, Kusuhara H, Endo C,Tohyama K, Miyajima M, Kitamura S, Sugiyama Y: Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier. Drug Metab Dispos, 2010, 38, 168-176.
24. Przeklasa-Muszyńska A, Dobrogowski J: Transdermal buprenorphine in the treatment of cancer and non-cancer pain - the results of multicenter studies in Poland. Pharmacol Rep, 2011, 63, 935-948.
25. Schinkel AH: P-glycoprotein, a gatekeeper in the bloodbrain barrier. Adv Drug Deliv Rev, 1999, 36, 179-194.
26. Suzuki T, Zaima C, Moriki Y, Fukami T, Tomono K: P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood-brain barrier. J Drug Target, 2007, 15, 67-74. (Pubitemid 47161333)
27. Tegeder I, Meier S, Burian M, Schmidt H, Geisslinger G, Lötsch J: Peripheral opioid analgesia in experimental human pain models. Brain, 2003, 126, 1092-1102. (Pubitemid 36522952)
28. Thompson SJ, Koszdin K, Bernards CM: Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology, 2000, 92, 1392-1399. (Pubitemid 30257201)
29. Tsuji A, Sakata A, Tamai I: Tissue distribution of the multidrug-resistance gene product P-glycoprotein and its physiological function (Japanese). Nippon Rinsho, 1997, 55, 1059-1063.
30. Tunblad K, Ederoth P, Gardenfors A, Hammarlund- Udenaes M, Nordstrom CH: Altered brain exposure of morphine in experimental meningitis studied with microdialysis. Acta Anaesthesiol Scand, 2004, 48, 294-301. (Pubitemid 38295340)
31. Wakako H, Takehiko M, Norikazu K, Chizuko Y, Shogo T, Shiroh K: Negative relationship between morphine analgesia and P-glycoprotein expression levels in the brain. J Pharmacol Sci, 2007, 105, 353-360.
32. Xie R, Hammarlund-Udenaes M, de Boer AG, de Lange EC: The role of P-glycoprotein in blood-brain barrier transport of morphine:transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. Br J Pharmacol, 1999, 128, 563-568. (Pubitemid 29504744)